188 related articles for article (PubMed ID: 28280620)
1. Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Borazanci E; Millis SZ; Kimbrough J; Doll N; Von Hoff D; Ramanathan RK
J Gastrointest Oncol; 2017 Feb; 8(1):164-172. PubMed ID: 28280620
[TBL] [Abstract][Full Text] [Related]
2. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
[TBL] [Abstract][Full Text] [Related]
3. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations.
Liu X; Mody K; de Abreu FB; Pipas JM; Peterson JD; Gallagher TL; Suriawinata AA; Ripple GH; Hourdequin KC; Smith KD; Barth RJ; Colacchio TA; Tsapakos MJ; Zaki BI; Gardner TB; Gordon SR; Amos CI; Wells WA; Tsongalis GJ
Clin Chem; 2014 Jul; 60(7):1004-11. PubMed ID: 24821835
[TBL] [Abstract][Full Text] [Related]
5. Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.
Tokunaga R; Xiu J; Johnston C; Goldberg RM; Philip PA; Seeber A; Naseem M; Lo JH; Arai H; Battaglin F; Puccini A; Berger MD; Soni S; Zhang W; Hwang JJ; Shields AF; Marshall JL; Baba H; Korn WM; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):3096-3103. PubMed ID: 30692096
[TBL] [Abstract][Full Text] [Related]
6. Tumor profiling of gastric and esophageal carcinoma reveal different treatment options.
Miura JT; Xiu J; Thomas J; George B; Carron BR; Tsai S; Johnston FM; Turaga KK; Gamblin TC
Cancer Biol Ther; 2015; 16(5):764-9. PubMed ID: 25778705
[TBL] [Abstract][Full Text] [Related]
7. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry features and molecular pathology of appendiceal neoplasms.
Mikaeel RR; Young JP; Tapia Rico G; Hewett PJ; Hardingham JE; Uylaki W; Horsnell M; Price TJ
Crit Rev Clin Lab Sci; 2021 Sep; 58(6):369-384. PubMed ID: 33569997
[TBL] [Abstract][Full Text] [Related]
9. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
10. Appendiceal goblet cell carcinoids and adenocarcinomas ex-goblet cell carcinoid are genetically distinct from primary colorectal-type adenocarcinoma of the appendix.
Jesinghaus M; Konukiewitz B; Foersch S; Stenzinger A; Steiger K; Muckenhuber A; Groß C; Mollenhauer M; Roth W; Detlefsen S; Weichert W; Klöppel G; Pfarr N; Schlitter AM
Mod Pathol; 2018 May; 31(5):829-839. PubMed ID: 29327707
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
12. Genomic Landscape of Appendiceal Neoplasms.
Ang CS; Shen JP; Hardy-Abeloos CJ; Huang JK; Ross JS; Miller VA; Jacobs MT; Chen IL; Xu D; Ali SM; Baumgartner J; Lowy A; Fanta P; Ideker T; Millis SZ; Harismendy O
JCO Precis Oncol; 2018; 2():. PubMed ID: 32913983
[TBL] [Abstract][Full Text] [Related]
13. Molecular Characterization of Appendiceal Goblet Cell Carcinoid.
Arai H; Baca Y; Battaglin F; Kawanishi N; Wang J; Soni S; Zhang W; Millstein J; Johnston C; Goldberg RM; Philip PA; Seeber A; Xiu J; Hwang JJ; Shields AF; Marshall JL; Korn WM; Lenz HJ
Mol Cancer Ther; 2020 Dec; 19(12):2634-2640. PubMed ID: 33037134
[TBL] [Abstract][Full Text] [Related]
14. Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
Meagher NS; Schuster K; Voss A; Budden T; Pang CNI; deFazio A; Ramus SJ; Friedlander ML
Gynecol Oncol; 2018 Sep; 150(3):527-533. PubMed ID: 30054102
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma.
Jones NL; Xiu J; Reddy SK; Burke WM; Tergas AI; Wright JD; Hou JY
Gynecol Oncol; 2015 Sep; 138(3):620-6. PubMed ID: 26123645
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei.
Shih IM; Yan H; Speyrer D; Shmookler BM; Sugarbaker PH; Ronnett BM
Am J Surg Pathol; 2001 Aug; 25(8):1095-9. PubMed ID: 11474297
[TBL] [Abstract][Full Text] [Related]
17. Genomic profile of appendiceal goblet cell carcinoid is distinct compared to appendiceal neuroendocrine tumor and conventional adenocarcinoma.
Wen KW; Grenert JP; Joseph NM; Shafizadeh N; Huang A; Hosseini M; Kakar S
Hum Pathol; 2018 Jul; 77():166-174. PubMed ID: 29634977
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
Topcagic J; Feldman R; Ghazalpour A; Swensen J; Gatalica Z; Vranic S
PLoS One; 2018; 13(1):e0191244. PubMed ID: 29324814
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
[TBL] [Abstract][Full Text] [Related]
20. A mutation spectrum that includes GNAS, KRAS and TP53 may be shared by mucinous neoplasms of the appendix.
Hara K; Saito T; Hayashi T; Yimit A; Takahashi M; Mitani K; Takahashi M; Yao T
Pathol Res Pract; 2015 Sep; 211(9):657-64. PubMed ID: 26160192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
